

KURZPROTOKOLL
CCTL019A2205B

Öffentlicher Titel	Langzeit-Follow-up-Studie nach Behandlung mit CAR T-Zellen
Wissenschaftl. Titel	Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 directed CAR T-Cell Therapy
Kurztitel	CCTL019A2205B
Studienart	multizentrisch, prospektiv, Therapiestudie, offen/unverblindet, einarmig, Pharma-Studie
Studienphase	Phase II/III
Erkrankung	Kinder: Leukämien und Lymphome: Rezidiert/refraktär
Einschlusskriterien	- All patients who have received CD19 CAR T-cell therapy, murine (CTL019) and/or humanized (CTL119) CD19-directed CAR T cell treatment, manufactured by Novartis or University of Pennsylvania (Penn) and participated in a Novartis or Penn sponsored treatment protocol or a Novartis managed access program - Patients who have provided informed consent for the long term follow up study prior to their study participation
Ausschlusskriterien	- There are no specific exclusion criteria for this study
Alter	2 Jahre und älter
Molekularer Marker	CD19
Sponsor	Novartis Pharma
Registrierung in anderen Studienregistern	ClinicalTrials.gov NCT02445222 (primäres Register) EudraCT 2014-001673-14
Links	zu den Ein- und Ausschlusskriterien